Uses of Tafsafe

Tafsafe medicine 25mg with active ingredient is Tenofovir Alafenamide used in the treatment of chronic hepatitis B. On the market today, there is a lot of information about the drug product Tafsafe 25mg, but it is still incomplete. To learn more about tafsafe 25mg, let's learn more in the article below.

Tafsafe with active ingredient tenofovir alafenamide is a newly developed tenofovir prodrug to improve renal safety when compared to tenofovir disoproxil. Both of these prodrugs were first engineered to coat the polar phosphoric acid group on tenofovir using a novel carbonyl oxygen ethyl oxygen binder to improve oral bioavailability and intestinal diffusion. Tenofovir alafenamide is an alanine ester that has been characterized to exhibit low systemic but high intracellular concentrations. It has been reported to produce a great antiviral effect at doses ten times lower than tenofovir disoproxil. Tenofovir alafenamide is indicated for the treatment of chronic hepatitis B, the treatment of HIV and the prevention of HIV infection.
Tenofovir alafenamide's potent inhibitory effect on hepatitis B virus replication has been demonstrated. Renal tolerability of tenofovir alafenamide was better when compared with its counterpart tenofovir disoproxil. In several clinical trials, tenofovir alafenamide was shown to have 5 times more potent antiviral activity against HIV-1 than tenofovir disoproxil.
Tenofovir alafenamide exhibits 91% lower plasma concentrations with approximately 20-fold higher intracellular presence when compared with tenofovir disoproxil. This is due to prolonged systemic exposure and higher intracellular accumulation of the active metabolite tenofovir diphosphate. Tenofovir alafenamide accumulates more in peripheral blood mononuclear cells than in erythrocytes. Once activated, there are various mechanisms of action of tenofovir including inhibition of viral polymerase, induction of chain termination, and inhibition of viral synthesis. Compared with the parent molecule, tenofovir, tenofovir alafenamide exhibits a lipophilic group that masks the negative charge of the parent molecule, which improves its oral bioavailability.
Tenofovir alafenamide is relatively stable in plasma and after administration of this prodrug, plasma concentrations of tenofovir are low. After entering the body, tenofovir alafenamide is rapidly absorbed in the intestine. When a single dose was administered, a peak concentration of 16 ng/ml of the parent compound, corresponding to approximately 73% of the dose, was observed after 2 hours with an AUC of 270 ng*h/mL.
Concomitant administration of tenofovir alafenamide with a high-fat meal increases intrabody exposure by approximately 65%. Tenofovir alafenamide has been registered for biliary elimination corresponding to 47% of the dose and renal elimination corresponding to approximately 36%. From a recovered dose in the urine, approximately 75% is expressed as unchanged tenofovir, followed by uric acid and a small dose of tenofovir alafenamide. On the other hand, in the feces, 99% of the recovered material corresponds to tenofovir. According to reports, the half-life of tenofovir alafenamide is 0.51 hours.

Tenofovir alafenamide is indicated for the treatment of chronic hepatitis B in adults with compensated liver disease. In combination with emtricitabine and other antiretroviral agents, it is indicated for the treatment of HIV infection.
The complete regimen for the treatment of patients with new HIV-1 infection or who have been virologically suppressed for at least 3 months and with no history of failure is the combination of tenofovir alafenamide, beit gravir, and emtricitabine. In addition, regimens that include tenofovir alafenamide with elvitegravir, cobicistat, emtricitabine or with emtricitabine, rilpivirine are used to treat HIV-1-infected persons over 12 years of age and without a history of ART or who have a history of viral suppression in at least 6 months without a history of treatment failure.

Usage of the drug Tafsafe 25mg
Oral administration. The drug should be taken with food. Dosage of the drug Tafsafe 25mg
Dosage is indicated under the guidance of the doctor. The recommended dosage is given as follows: 1 tablet/day. The duration of treatment for HBeAg-positive patients without cirrhosis is at least 6-12 months. During treatment, regular follow-up re-evaluation is required to detect viral recurrence. Re-evaluation is also recommended in patients treated for more than 2 years, to ensure that the initially prescribed dose is still effective. For patients 65 years of age and older, no dose adjustment is required. Similarly, for patients with renal failure with creatinine clearance ≥ 15 ml/min or in patients on hemodialysis. For patients on hemodialysis, the drug should be used after dialysis. For patients with renal failure with creatinine clearance less than 15 ml/min who are not on dialysis, tafsafe should not be used. For patients weighing less than 35 kg and children under 12 years of age, use is not recommended because there are not enough data on safety. The dosage information in this article is for reference only, it should be based on the progress of the disease as well as the patient's condition.
Undesirable effects of the drug tafsafe 25mg Some side effects may be encountered when using tefsafe: The most common side effect is headache and dizziness. Gastrointestinal symptoms: diarrhea, abdominal pain, bloating, flatulence, nausea, vomiting. Increased liver enzyme ALT. Skin symptoms include itching, rash. Whole body fatigue or muscle pain.
Drug Interactions Some interactions with Tenofovir Alafenamide include:
Caution when co-administered with medicines containing Tenofovir disoproxil, Tenofovir alafenamide or Adefovir dipivoxil. P-gp inducers and inhibitors such as Rifabutin, Rifampicin, Carbamazepine, Phenobarbital or St. John's wort: alters plasma concentrations of Tenofovir alafenamide. To ensure the safety and effectiveness of your medicine, list with your doctor all the medicines, supplements and traditional medicines you are taking.

Human and animal studies have shown that use of Tenofovir alafenamide has no reproductive toxicity. No increased risk of malformation or fetal or neonatal toxicity. Therefore, for pregnant women use when necessary.
Animal studies have shown that the drug is secreted in breast milk, therefore caution should be exercised in nursing mothers, although it is not known whether the drug is excreted in human milk.
If you experience dizziness as a side effect, which may interfere with activities that require attention, such as driving or operating machinery
The drug does not reduce the risk of transmitting HBV to others through sex or blood-borne infections . The risk of adverse events is higher in HBV-infected persons with decompensated liver and in patients with a Child Pugh Turcotte score (CPT) > 9. In treatment-discontinued exacerbations of hepatitis have been observed. Not recommended in patients with CrCl less than 15 mL/min who are not on hemodialysis. May increase risk of nephrotoxicity. For patients with co-infection with HIV, hepatitis C and D, caution should be exercised. Above is important information about Tafsafe drug. To ensure safety before using you should consult your doctor to ensure the use of the drug to ensure the health of the patient.